Cargando…

Use of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetics: Are the Benefits Worth the Risks?

The mainstay of treatment for type 1 diabetes is insulin. The use of insulin for tight glycemic control is the key to preventing micro- and macrovascular complications, but it can also lead to hypoglycemic episodes. Therefore, there is a need for the introduction of a drug that can maintain glucose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fatima, Tehreem, Sedrakyan, Surik, Awan, Muhammad R, Khatun, Mst. Khaleda, Rana, Dibyata, Jahan, Nusrat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2020
Materias:	Endocrinology/Diabetes/Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522056/ https://www.ncbi.nlm.nih.gov/pubmed/33005503 http://dx.doi.org/10.7759/cureus.10076

Ejemplares similares

Evaluation of the Risk of Getting Peripheral Artery Disease in Rheumatoid Arthritis and the Selection of Appropriate Diagnostic Methods
por: Sedrakyan, Surik, et al.
Publicado: (2020)

Pituitary Stalk Interruption Syndrome
por: Fatima, Tehreem, et al.
Publicado: (2020)

Psychological Spectrum Experienced by Heart Failure Patients After Left Ventricular Assist Device Implantation
por: Okam, Nkechi A, et al.
Publicado: (2020)

Pharmacological Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: Where Do We Stand Now?
por: Ahmad, Wiqas, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Continuous Glucose Monitoring Versus Self-monitoring of Blood Glucose in Type 2 Diabetes Mellitus: A Systematic Review with Meta-analysis
por: Janapala, Rajesh Naidu, et al.
Publicado: (2019)

Sodium-Glucose Linked Transporter Inhibitors as a Cause of Euglycemic Diabetic Ketoacidosis on a Background of Starvation
por: Tauseef, Abubakar, et al.
Publicado: (2020)

Faster Insulin Aspart for Continuous Subcutaneous Insulin Infusion: Is It Worth It?
por: Rosinha, Patrícia, et al.
Publicado: (2022)

Sodium-Glucose Co-transporter 2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis After Bariatric Surgery: A Case and Literature Review
por: Kapila, Vaishali, et al.
Publicado: (2021)

Use of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes
por: Jain, Rajesh, et al.
Publicado: (2022)

Role of Selective Sodium-Glucose Co-Transporter-2 Inhibitors in Managing Cardio-Renal Complications in Type 2 Diabetes Mellitus: Beyond Glycemic Control
por: Onyali, Chike B, et al.
Publicado: (2021)

Obstructive Sleep Apnea and Cardiovascular Morbidities: A Review Article
por: Rana, Dibyata, et al.
Publicado: (2020)

Sodium-glucose Cotransporter-2 Inhibitors and Euglycaemic Diabetic Ketoacidosis in the Perioperative Period: Case Report
por: Jhaveri, Urmita, et al.
Publicado: (2019)

A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors
por: Chaurasia, Pallavi Prakash, et al.
Publicado: (2021)

Prolonged Glucosuria With Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Case Report and Review of Literature
por: Aggarwal, Ankita, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis Followed by Excessively Low Carbohydrate Diet
por: Tsutsui, Erika, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers
por: Somagutta, Manoj R, et al.
Publicado: (2021)

Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes
por: Hussain, Mazhar, et al.
Publicado: (2021)

Baseline Characteristics Associated With Sodium-Glucose Cotransporter Inhibitor Prescriptions in Type 2 Diabetic Patients in Jazan, Saudi Arabia
por: Somaili, Mohammed, et al.
Publicado: (2022)

Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India
por: Maradia, Jay, et al.
Publicado: (2023)

Euglycemic Diabetic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor Use Post-Bariatric Surgery: A Brief Review of the Literature
por: Iqbal, Qasim Z, et al.
Publicado: (2020)

Type 2 Diabetes Remission and Substantial Body Weight Reduction Achieved with Metformin and a Sodium-Glucose Cotransporter 2 Inhibitor
por: Sugiyama, Seigo, et al.
Publicado: (2020)

Postoperative Euglycemic Ketoacidosis in Type 2 Diabetes Associated with Sodium-Glucose Cotransporter 2 Inhibitor: Insights Into Pathogenesis and Management Strategy
por: Chandrakumar, Harshith P, et al.
Publicado: (2021)

A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
por: Patel, Khyati, et al.
Publicado: (2022)

A Rare but Life-Threatening Case of Fournier’s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin
por: Jahir, Tahmina, et al.
Publicado: (2022)

Early Presentation of a Rare Complication of Sodium-Glucose Cotransporter-2 Inhibitors 10 Days After Initiation: Case Report and Literature Review
por: Elshimy, Ghada, et al.
Publicado: (2019)

Intermittent Fasting: A User-Friendly Method for Type 2 Diabetes Mellitus
por: Saeed, Mahreen, et al.
Publicado: (2021)

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
por: Donnan, Jennifer R, et al.
Publicado: (2019)

Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium–Glucose Co-transporter-2 Inhibitors
por: Neumiller, Joshua J, et al.
Publicado: (2022)

Hypertriglyceridemia-Induced Acute Pancreatitis, Euglycemic Diabetic Ketoacidosis and COVID-19 Infection in a Patient With Type 2 Diabetes Taking a Sodium-Glucose Cotransporter 2 Inhibitor
por: Acevedo-Mendez, Bernardo A, et al.
Publicado: (2021)

The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus
por: Brunton, S. A.
Publicado: (2015)

The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes
por: Shami, Dalia, et al.
Publicado: (2023)

A Retrospective Study to Examine the Correlation of Bioelectrical Impedance Analysis with Shear-wave Elastography in Indian Patients with Non-alcoholic Fatty Liver Disease and Diabetes on Background Sodium-glucose Cotransporter-2 Inhibitor Therapy
por: Roy, Sayak, et al.
Publicado: (2019)

Patterns of Abnormal Glucose Metabolism in Acromegaly and Impact of Treatment Modalities on Glucose Metabolism
por: Khan, Sajjad Ali, et al.
Publicado: (2021)

ODP252 Urosepsis and Sodium-Glucose Co-Transporter-2 Inhibitors: A Systematic Review and Meta-Analysis
por: Prasongdee, Klaorat, et al.
Publicado: (2022)

Continuous Glucose Monitoring vs. Capillary Blood Glucose in Hospitalized Type 2 Diabetes Patients
por: Veríssimo, David, et al.
Publicado: (2023)

The Benefits Outweigh the Risks of Treating Hypercholesterolemia: The Statin Dilemma
por: Hussain, Azhar, et al.
Publicado: (2023)

The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials
por: Storgaard, Heidi, et al.
Publicado: (2014)

Relationship Between Estimated Average Glucose (eAG) and Fasting Plasma Glucose in a Cohort of Pakistani Diabetic Subjects
por: Ram, Nanik, et al.
Publicado: (2021)

Glycemic Control and the Weight Benefit of a Daily 7 mg Dose of Oral Semaglutide Versus an Alternate-Day 14 mg Dose of Oral Semaglutide From an Ambulatory Glucose Monitoring Data: A Retrospective Cohort Study From Eastern India
por: RoyChaudhuri, Soumyabrata, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8cpb3gfq7adlsfsjag007ghaes